Dr. Doebele is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8000 Jarvis Ave.
Ste 204
Newark, CA 94560Phone+1 510-255-2171- Is this information wrong?
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2004 - 2007- University of ChicagoResidency, Internal Medicine, 2001 - 2004
Perelman School of Medicine at the University of PennsylvaniaClass of 2001
Certifications & Licensure
CO State Medical License 2008 - 2025
IL State Medical License 2001 - 2008
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer Start of enrollment: 2012 Jan 23
- Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer Start of enrollment: 2017 Dec 13
Publications & Presentations
PubMed
- MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.Nan Chen, Logan C Tyler, Anh T Le, Eric A Welsh, Bin Fang, Andrew Elliott, Kurtis D Davies, Thomas Danhorn, Gregory J Riely, Marc Ladanyi, Eric B Haura, Doebele, R.> ;Molecular Cancer Therapeutics. 2024 Jan 3
- Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.Yi Liao, Lily L Remsing Rix, Xueli Li, Bin Fang, Victoria Izumi, Eric A Welsh, Andrii Monastyrskyi, Eric B Haura, John M Koomen, Robert C Doebele, Uwe Rix> ;Cell Chemical Biology. 2024 Feb 15
- Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.Tara L Peters, Nan Chen, Logan C Tyler, Anh T Le, Anastasios Dimou, Robert C Doebele> ;Thoracic Cancer. 2023 Nov 1
- Join now to see all
Lectures
- Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and c...2019 ASCO Annual Meeting - 6/1/2019
- Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome's positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Chutes & Ladders—Another Novartis Exec Answers the Biotech Call, This Time for Gene Therapy Startup TevardMay 21st, 2021- BioSpace Movers & Shakers, May 21May 20th, 2021
- Rain Therapeutics Strengthens the Board of Directors and Scientific Advisory Board with Key Appointments of Leading Industry and Research ExpertsApril 13th, 2021
- Join now to see all
Hospital Affiliations
University of Colorado HospitalAurora, Colorado
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
